AR098389A1 - Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents
Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienenInfo
- Publication number
- AR098389A1 AR098389A1 ARP140104246A ARP140104246A AR098389A1 AR 098389 A1 AR098389 A1 AR 098389A1 AR P140104246 A ARP140104246 A AR P140104246A AR P140104246 A ARP140104246 A AR P140104246A AR 098389 A1 AR098389 A1 AR 098389A1
- Authority
- AR
- Argentina
- Prior art keywords
- copolymers
- pharmaceutically acceptable
- polyethylene glycol
- complex
- fulvestrant
- Prior art date
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 229960002258 fulvestrant Drugs 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 229920001983 poloxamer Polymers 0.000 abstract 8
- 239000002202 Polyethylene glycol Substances 0.000 abstract 5
- 239000008139 complexing agent Substances 0.000 abstract 5
- 229920001577 copolymer Polymers 0.000 abstract 5
- 229920001223 polyethylene glycol Polymers 0.000 abstract 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 abstract 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 abstract 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 2
- 229920000578 graft copolymer Polymers 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960000502 poloxamer Drugs 0.000 abstract 2
- 235000017281 sodium acetate Nutrition 0.000 abstract 2
- 239000001632 sodium acetate Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 abstract 1
- DEISLDFBMJLVTC-UHFFFAOYSA-N 8-(difluoromethoxy)-1-ethyl-6-fluoro-7-[4-(2-methoxyphenyl)piperazin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound FC(F)OC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1C1=CC=CC=C1OC DEISLDFBMJLVTC-UHFFFAOYSA-N 0.000 abstract 1
- 206010055113 Breast cancer metastatic Diseases 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 229920005682 EO-PO block copolymer Polymers 0.000 abstract 1
- 229910016860 FaSSIF Inorganic materials 0.000 abstract 1
- 229910005429 FeSSIF Inorganic materials 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008118 PEG 6000 Substances 0.000 abstract 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 abstract 1
- 229920002675 Polyoxyl Polymers 0.000 abstract 1
- 229920003082 Povidone K 90 Polymers 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 229920001304 Solutol HS 15 Polymers 0.000 abstract 1
- 229920002359 Tetronic® Polymers 0.000 abstract 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 abstract 1
- -1 acetate-polyethylene Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 229920006187 aquazol Polymers 0.000 abstract 1
- 239000012861 aquazol Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229920001400 block copolymer Polymers 0.000 abstract 1
- 230000000112 colonic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000005690 diesters Chemical class 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229940072106 hydroxystearate Drugs 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 abstract 1
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Abstract
Fórmulas de complejos farmacéuticamente aceptables que comprenden complejos de Fulvestrant, o una sal, o sus derivados y excipientes farmacéuticamente aceptables. Procesos para su preparación y composiciones farmacéuticas que los contienen. Las fórmulas de los complejos tienen propiedades fisicoquímicas, que hacen posible su disponibilidad por vía oral y que la administración oral del compuesto se utilice para el tratamiento del cáncer de mama metastático positivo para receptores hormonales en mujeres posmenopáusicas con evolución de la enfermedad después de una terapia antiestrogénica. Reivindicación 1: Un complejo estable, caracterizado porque comprende un ingrediente activo seleccionado del grupo de Fulvestrant, sus sales o sus derivados; y por lo menos un agente complejante seleccionado del grupo de copolímeros de injertos de polivinilcaprolactama-acetato de polivinilo-polietilenglicol; poloxámeros; polivinilpirrolidona; copolímeros de vinilpirrolidona y acetato de vinilo; y ácido poli(maIeico-co-metil-vinil-éter); donde dicho complejo presenta por lo menos una de las siguientes propiedades: a) se puede volver a dispersar instantáneamente en medios fisiológicos relevantes; b) tiene una mayor velocidad de disolución; c) es estable en una forma sólida y en una solución y/o dispersión coloidal; d) tiene una solubilidad aparente en agua de por lo menos 1 mg/ml; e) presenta un carácter de rayos X amorfo en la forma sólida; f) tiene una permeabilidad PAMPA de por lo menos 0,5 x 10⁻⁶ cm/s cuando se dispersa en medios biorrelevantes FaSSIF o FeSSIF, que no disminuye en el tiempo por al menos 1 mes; g) se caracteriza por un espectro infrarrojo (ATR) que tiene picos de absorción principales/característicos por lo menos en 1412 cm⁻¹, 1197 cm⁻¹ y 1105 cm⁻¹; y una falta de picos de absorción característicos en 1611 cm⁻¹ y 1504 cm⁻¹; y h) dicho complejo se encuentra biodisponible por vía oral. Reivindicación 2: El complejo de acuerdo con la reivindicación 1, caracterizado porque dicho agente complejante se selecciona entre glicéridos de polietilenglicol compuestos por mono, di y triglicéridos y mono y diésteres de polietilenglicol (por ejemplo; Gelucire 44/14, Gelucire 50/13), hidroxipropilcelulosa (por ejemplo; Klucell EF, Klucell LF), poloxámeros (copolímeros de bloques de óxido de etileno y óxido de propileno) (por ejemplo; Lutrol F127), copolímero de vinilpirrolidona / acetato de vinilo (por ejemplo; Luviskol VA64), polietilenglicol (por ejemplo; PEG2000, PEG6000), poli(2-etil-2-oxazolina) (por ejemplo; PEOX50, PEOX500), polivinilpirrolidona (por ejemplo; Plasdona K-12, PVP 40, PVP K90, PVP 10), copolímeros de bloques basados en óxido de etileno y óxido de propileno (por ejemplo; Pluronic PE10500, Pluronic PE6800, Pluronic F108), ácido poli(maleico / metil vinil éter) (PMAMVE), (copolímeros de injertos de polivinilcaprolactama-acetato de polivinilo-polietilenglicol (por ejemplo; Soluplus), hidroxiestearato de polioxilo 15 (por ejemplo; Solutol HS15), copolímero de bloques de óxido de etileno / óxido de propileno (por ejemplo; Tetronic 1107) y succinato de d-a tocoferil polietilenglicol 1000 (TPGS), preferiblemente el agente complejante es un poloxámero. Reivindicación 6: Un complejo de acuerdo con cualquiera de las reivindicaciones 1 a 5, caracterizado porque comprende un agente complejante que es un poloxámero y un excipiente farmacéuticamente aceptable que es acetato de sodio, en una cantidad total que varía en un rango de entre aproximadamente 1,0% en peso y aproximadamente 95,0% en peso basado en el peso total del complejo. Reivindicación 7: Un proceso para la preparación del complejo de acuerdo con cualquiera de las reivindicaciones 1 a 6, caracterizado porque comprende los pasos de mezclar una solución de Fulvestrant, su sal o sus derivados, y por lo menos un agente complejante seleccionado del grupo de copolímeros de injertos de polivinilcaprolactama-acetato de polivinilo-polietilenglicol; poloxámeros; polivinilpirrolidona; copolímeros de vinilpirrolidona y acetato de vinilo; y ácido poli(maIeico-co-metil-vinil-éter) en un solvente farmacéuticamente aceptable con una solución acuosa que contiene por lo menos un excipiente farmacéuticamente aceptable seleccionado entre laurilsulfato de sodio y acetato de sodio. Reivindicación 11: Una composición farmacéutica, caracterizada porque comprende el complejo de acuerdo con cualquiera de las reivindicaciones 1 a 6 junto con un vehículo farmacéuticamente aceptable. Reivindicación 12: Una composición farmacéutica de acuerdo con la reivindicación 11, caracterizada porque dicha composición es adecuada para una administración por vía oral, pulmonar, rectal, colónica, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, ótica, local, bucal, nasal o tópica, preferiblemente la composición es adecuada para una administración oral. Reivindicación 16: Un método para reducir la dosificación terapéuticamente eficaz de Fulvestrant en comparación con una inyección intramuscular, caracterizado porque dicho método comprende la administración oral de una composición farmacéutica de acuerdo con las reivindicaciones 11 ó 12.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1300646A HUP1300646A2 (en) | 2013-11-12 | 2013-11-12 | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098389A1 true AR098389A1 (es) | 2016-05-26 |
Family
ID=89991320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104246A AR098389A1 (es) | 2013-11-12 | 2014-11-11 | Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150132388A1 (es) |
| EP (1) | EP3068377A1 (es) |
| AR (1) | AR098389A1 (es) |
| HU (1) | HUP1300646A2 (es) |
| TW (1) | TW201540303A (es) |
| WO (1) | WO2015071836A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1600270A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
| HUP1600271A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
| US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
| HUP1600269A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
| US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| AU2018329202B2 (en) | 2017-09-11 | 2022-10-27 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4570357B2 (ja) * | 2001-07-06 | 2010-10-27 | ライフサイクル ファーマ エー／エス | 制御された凝集 |
| WO2005014162A1 (en) * | 2003-08-04 | 2005-02-17 | Camurus Ab | Method for improving the properties of amphiphile particles |
| DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
| WO2007033434A1 (en) * | 2005-09-26 | 2007-03-29 | Hospira Australia Pty Ltd | Fulvestrant formulation |
| US20100166872A1 (en) | 2005-10-21 | 2010-07-01 | Amarjit Singh | Novel improved compositions for cancer therapy |
| CA2668725A1 (en) * | 2006-11-09 | 2008-05-22 | Ore Pharmaceuticals Inc. | Breast cancer screening and treatment methods |
| US7687487B2 (en) * | 2007-04-19 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same |
| PL2200588T3 (pl) | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
| KR20100121505A (ko) * | 2008-03-07 | 2010-11-17 | 싸이도우스 엘엘씨. | 플배스트랜 제제 |
| HU230862B1 (hu) | 2008-04-28 | 2018-10-29 | DARHOLDING Vagyonkezelő Kft | Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására |
| JP5809624B2 (ja) * | 2009-08-31 | 2015-11-11 | シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | フルベストラントナノスフェア／ミクロスフェア並びにその調製方法及び使用 |
| EP2616078B1 (en) | 2010-09-16 | 2019-12-25 | Shimoda Biotech (Pty) Ltd | Fulvestrant compositions and methods of use |
| US9029582B2 (en) | 2011-05-20 | 2015-05-12 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| WO2013102144A2 (en) * | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| CN102600064A (zh) | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
-
2013
- 2013-11-12 HU HU1300646A patent/HUP1300646A2/hu unknown
-
2014
- 2014-11-11 US US14/538,184 patent/US20150132388A1/en not_active Abandoned
- 2014-11-11 AR ARP140104246A patent/AR098389A1/es unknown
- 2014-11-12 TW TW103139255A patent/TW201540303A/zh unknown
- 2014-11-12 EP EP14808728.1A patent/EP3068377A1/en not_active Withdrawn
- 2014-11-12 WO PCT/IB2014/065986 patent/WO2015071836A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015071836A1 (en) | 2015-05-21 |
| US20150132388A1 (en) | 2015-05-14 |
| TW201540303A (zh) | 2015-11-01 |
| EP3068377A1 (en) | 2016-09-21 |
| HUP1300646A2 (en) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098389A1 (es) | Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen | |
| JP2018504443A5 (es) | ||
| ES2622471T3 (es) | Compuestos y procedimientos para la administración de análogos de prostaciclina | |
| ES2784843T3 (es) | Complejos de Sirolimus y sus derivados, procedimiento para la preparación de los mismos y composiciones farmacéuticas que los contienen | |
| AR103653A1 (es) | Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen | |
| JP2020512328A (ja) | 新規組成物および方法 | |
| Seo et al. | Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect | |
| JP2016503030A5 (es) | ||
| JP2017505822A5 (es) | ||
| RU2013102030A (ru) | Композиции наноструктурированного апрепитанта, способ их получения и содержащие их фармацевтические композиции | |
| JP2017519803A (ja) | 舌下ナロキソンスプレー | |
| BR112014011981B1 (pt) | FORMULAgOES FARMACEUTICAS SOLIDAS ORAIS, SEUS PROCESSOS DE PREPARAgAO E USOS | |
| US10376591B2 (en) | Formulations and carrier systems including farnesylthiosalicylic moieties | |
| JP2017528497A5 (es) | ||
| KR20200023473A (ko) | 두타스테라이드를 포함하는 고형 제제 및 이의 제조방법 | |
| WO2017133662A1 (zh) | 一种紫杉醇药物组合物及其药物制剂、制备方法和用途 | |
| RU2021102950A (ru) | Твердые фармацевтические композиции для лечения вируса гепатита с | |
| CN102228433B (zh) | 过饱和自微乳制剂及其制备方法和应用 | |
| AU2015250470B2 (en) | Active ingredient (I) containing composition and method for preparing same | |
| JP2019531344A5 (es) | ||
| JP2003055223A (ja) | 安定化された組成物 | |
| JP2003055222A (ja) | 安定化された組成物 | |
| Kasashima et al. | Oral sustained release of a hydrophilic drug using the lauryl sulfate salt/complex | |
| KR20220031909A (ko) | 약물을 포함하는 수성 조성물의 pH를 안정화하는 방법 | |
| Sharma et al. | Thermoreversible insitu gel for nasal drug delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |